Evoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell

MT Newswires Live

Oct 28, 2024

Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.

The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.

It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.

Shares of the drug developer more than doubled in premarket activity.

Price: 11.50, Change: +6.37, Percent Change: +124.17

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2478865104"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478865104\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478865104?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478865104","market":"fut","top_or_hot":-1,"title":"Evoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.</p><p>The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.</p><p>It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.</p><p>Shares of the drug developer more than doubled in premarket activity.</p><p>Price: 11.50, Change: +6.37, Percent Change: +124.17</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Says Study Showed Gimoti Reduces Emergency Visits in Diabetic Gastroparesis Patients Using GLP-1; Shares Surge Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-28 19:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.</p><p>The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.</p><p>It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.</p><p>Shares of the drug developer more than doubled in premarket activity.</p><p>Price: 11.50, Change: +6.37, Percent Change: +124.17</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2478865104","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478865104","pubTimestamp":1730116757,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Evoke Pharma  said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.Shares of the drug developer more than doubled in premarket activity.Price: 11.50, Change: +6.37, Percent Change: +124.17","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLP":"Global Partners Lp","BK4144":"石油与天然气的储存和运输","BK4007":"制药","EVOK":"Evoke Pharma Inc.","BK4590":"PTP"},"translate_title":"Evoke Pharma表示，研究表明Gimoti可以减少使用GLP-1的糖尿病胃轻瘫患者的急诊次数；盘前股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":1,"GLP":1},"content_text":"Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.Shares of the drug developer more than doubled in premarket activity.Price: 11.50, Change: +6.37, Percent Change: +124.17","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}